214 related articles for article (PubMed ID: 36015371)
1. Development of Inhalable ATRA-Loaded PLGA Nanoparticles as Host-Directed Immunotherapy against Tuberculosis.
Bahlool AZ; Fattah S; O'Sullivan A; Cavanagh B; MacLoughlin R; Keane J; O'Sullivan MP; Cryan SA
Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015371
[TBL] [Abstract][Full Text] [Related]
2. Microfluidics produced ATRA-loaded PLGA NPs reduced tuberculosis burden in alveolar epithelial cells and enabled high delivered dose under simulated human breathing pattern in 3D printed head models.
Bahlool AZ; Cavanagh B; Sullivan AO; MacLoughlin R; Keane J; Sullivan MPO; Cryan SA
Eur J Pharm Sci; 2024 May; 196():106734. PubMed ID: 38417586
[TBL] [Abstract][Full Text] [Related]
3. Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection.
O'Connor G; Krishnan N; Fagan-Murphy A; Cassidy J; O'Leary S; Robertson BD; Keane J; O'Sullivan MP; Cryan SA
Eur J Pharm Biopharm; 2019 Jan; 134():153-165. PubMed ID: 30385419
[TBL] [Abstract][Full Text] [Related]
4. All
Bahlool AZ; Grant C; Cryan SA; Keane J; O'Sullivan MP
Curr Res Immunol; 2022; 3():54-72. PubMed ID: 35496824
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. Dynamic mucus penetrating microspheres for efficient pulmonary delivery and enhanced efficacy of host defence peptide (HDP) in experimental tuberculosis.
Sharma A; Vaghasiya K; Gupta P; Singh AK; Gupta UD; Verma RK
J Control Release; 2020 Aug; 324():17-33. PubMed ID: 32418903
[TBL] [Abstract][Full Text] [Related]
7. All-trans Retinoic Acid Augments Autophagy during Intracellular Bacterial Infection.
Coleman MM; Basdeo SA; Coleman AM; Cheallaigh CN; Peral de Castro C; McLaughlin AM; Dunne PJ; Harris J; Keane J
Am J Respir Cell Mol Biol; 2018 Nov; 59(5):548-556. PubMed ID: 29852080
[TBL] [Abstract][Full Text] [Related]
8. An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis.
O'Leary S; Bahlool AZ; O'Connor G; Cryan SA; Keane JM; O'Sullivan MP
J Vis Exp; 2021 Aug; (174):. PubMed ID: 34459817
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Mycobacterium tuberculosis-Infected Macrophages with Poly(Lactic-Co-Glycolic Acid) Microparticles Drives NFκB and Autophagy Dependent Bacillary Killing.
Lawlor C; O'Connor G; O'Leary S; Gallagher PJ; Cryan SA; Keane J; O'Sullivan MP
PLoS One; 2016; 11(2):e0149167. PubMed ID: 26894562
[TBL] [Abstract][Full Text] [Related]
10. Host-Directed Therapeutic Strategies for Tuberculosis.
Kolloli A; Subbian S
Front Med (Lausanne); 2017; 4():171. PubMed ID: 29094039
[TBL] [Abstract][Full Text] [Related]
11. Mixed metal oxide nanoparticles inhibit growth of Mycobacterium tuberculosis into THP-1 cells.
Jafari AR; Mosavi T; Mosavari N; Majid A; Movahedzade F; Tebyaniyan M; Kamalzadeh M; Dehgan M; Jafari S; Arastoo S
Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S181-S183. PubMed ID: 28043541
[TBL] [Abstract][Full Text] [Related]
12. Effect of Oxygen Flow on Aerosol Delivery From a Nebulizer With a Holding Chamber.
Sarhan RM; Elberry AA; Abdelwahab NS; Rabea H; Salem MN; Abdelrahim ME
Respir Care; 2019 Dec; 64(12):1508-1515. PubMed ID: 31387895
[TBL] [Abstract][Full Text] [Related]
13. Harnessing the mTOR Pathway for Tuberculosis Treatment.
Singh P; Subbian S
Front Microbiol; 2018; 9():70. PubMed ID: 29441052
[TBL] [Abstract][Full Text] [Related]
14. Host-Directed Therapies for Tuberculosis.
Jeong EK; Lee HJ; Jung YJ
Pathogens; 2022 Nov; 11(11):. PubMed ID: 36365041
[TBL] [Abstract][Full Text] [Related]
15. Host-Directed Therapy as a Novel Treatment Strategy to Overcome Tuberculosis: Targeting Immune Modulation.
Ahmed S; Raqib R; Guðmundsson GH; Bergman P; Agerberth B; Rekha RS
Antibiotics (Basel); 2020 Jan; 9(1):. PubMed ID: 31936156
[TBL] [Abstract][Full Text] [Related]
16. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model.
Suarez S; O'Hara P; Kazantseva M; Newcomer CE; Hopfer R; McMurray DN; Hickey AJ
Pharm Res; 2001 Sep; 18(9):1315-9. PubMed ID: 11683246
[TBL] [Abstract][Full Text] [Related]
17. Targeting of myeloid-derived suppressor cells by all-trans retinoic acid as host-directed therapy for human tuberculosis.
Leukes VN; Dorhoi A; Malherbe ST; Maasdorp E; Khoury J; McAnda S; Walzl G; du Plessis N
Cell Immunol; 2021 Jun; 364():104359. PubMed ID: 33865151
[TBL] [Abstract][Full Text] [Related]
18. Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against
Hakkimane SS; Shenoy VP; Gaonkar SL; Bairy I; Guru BR
Int J Nanomedicine; 2018; 13():4303-4318. PubMed ID: 30087562
[TBL] [Abstract][Full Text] [Related]
19. Development of Rifapentine-Loaded PLGA-Based Nanoparticles: In vitro Characterisation and in vivo Study in Mice.
Liang Q; Xiang H; Li X; Luo C; Ma X; Zhao W; Chen J; Tian Z; Li X; Song X
Int J Nanomedicine; 2020; 15():7491-7507. PubMed ID: 33116484
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
